Skip to main content

Advertisement

SpringerLink
Log in

Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Tofacitinib has only been available in China for 2 years to treat rheumatoid arthritis (RA). Our purpose was to compare real-world effectiveness of tofacitinib with that of disease-modifying anti-rheumatic drugs (DMARDs) in Chinese patients with RA. The records of patients with RA treated at Guangdong Provincial People’s Hospital between July 2017 and September 2019 were retrospectively reviewed. Patients were divided into those treated with tofacitinib, biological DMARDs (bDMARDs), and conventional synthetic DMARDs (csDMARDs). Clinical disease activity index (CDAI), simplified disease activity index (SDAI), health assessment questionnaire-disability index (HAQ-DI), visual analog scale (VAS) pain score, patient global assessment of disease activity (PtGA), physician global assessment of disease activity (PhGA), and swollen joint and tender joint count were compared among the groups up to 12 months of treatment. A total of 150 patients were included: 63 were treated with tofacitinib, 48 with bDMARDs, and 39 with csDMARDs. Tofacitinib was first-line treatment in 26.98% of patients, second-line treatment in 49.21%, and third-line treatment in 26.98%. Patients in the tofacitinib group had significantly higher disease duration (6.11 ± 6.97 years) than those in the other groups. All disease indices in the three groups decreased with time, indicating improvement of symptoms, with no differences among the groups at 12 months. Tofacitinib appeared to improve symptoms more rapidly than other treatments; however, differences in disease indices were not significant. This real-world study suggests that tofacitinib is rapidly effective and that the effects are sustained after 12 months in Chinese patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

All the data and materials have been presented in the main paper.

Code availability

Not applicable.

References

  1. Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA J Am Med Assoc 320:1360–1372

    Article  Google Scholar 

  2. Wasserman A (2018) Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician 97:455–462

    PubMed  Google Scholar 

  3. Littlejohn EA, Monrad SU (2018) Early diagnosis and treatment of rheumatoid arthritis. Prim Care Clin Off Pract 45:237–255

    Article  Google Scholar 

  4. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

    Article  PubMed  Google Scholar 

  5. Whittle SL, Colebatch AN, Buchbinder R et al (2012) Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e initiative. Rheumatology 51:1416–1425. https://doi.org/10.1093/rheumatology/kes032

    Article  PubMed  PubMed Central  Google Scholar 

  6. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637. https://doi.org/10.1136/ard.2009.123919

    Article  PubMed  Google Scholar 

  7. Sung YK, Yoshida K, Prince FHM et al (2019) Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS One 14:e0214981. https://doi.org/10.1371/journal.pone.0214981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nagy G, van Vollenhoven RF (2015) Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther 17:181

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kawalec P, Śladowska K, Malinowska-Lipień I et al (2018) European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 14:15–29

    Article  CAS  PubMed  Google Scholar 

  10. Fleischmann R, Cutolo M, Genovese MC et al (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617–629. https://doi.org/10.1002/art.33383

    Article  CAS  PubMed  Google Scholar 

  11. Kremer JM, Bloom BJ, Breedveld FC et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895–1905. https://doi.org/10.1002/art.24567

    Article  CAS  PubMed  Google Scholar 

  12. Kremer JM, Cohen S, Wilkinson BE et al (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64:970–981. https://doi.org/10.1002/art.33419

    Article  CAS  PubMed  Google Scholar 

  13. Tanaka Y, Suzuki M, Nakamura H et al (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 63:1150–1158. https://doi.org/10.1002/acr.20494

    Article  CAS  Google Scholar 

  14. Tanaka Y, Takeuchi T, Yamanaka H et al (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 25:514–521. https://doi.org/10.3109/14397595.2014.995875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460. https://doi.org/10.1016/S0140-6736(12)61424-X

    Article  CAS  PubMed  Google Scholar 

  16. Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495–507. https://doi.org/10.1056/NEJMoa1109071

    Article  CAS  PubMed  Google Scholar 

  17. Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253–261. https://doi.org/10.7326/0003-4819-159-4-201308200-00006

    Article  PubMed  Google Scholar 

  18. Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386. https://doi.org/10.1056/NEJMoa1310476

    Article  CAS  PubMed  Google Scholar 

  19. Van Der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559–570. https://doi.org/10.1002/art.37816

    Article  CAS  PubMed  Google Scholar 

  20. Van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508–519. https://doi.org/10.1056/NEJMoa1112072

    Article  CAS  PubMed  Google Scholar 

  21. Wollenhaupt J, Silverfield J, Lee Prof EB et al (2014) Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41:837–852. https://doi.org/10.3899/jrheum.130683

    Article  CAS  PubMed  Google Scholar 

  22. Yamanaka H, Tanaka Y, Takeuchi T et al (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 18:34. https://doi.org/10.1186/s13075-016-0932-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chinese Rheumatology Association (2018) 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 57:242–251. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.04.004

    Article  Google Scholar 

  24. Kim HS, Lee S, Kim JH (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 33:e213. https://doi.org/10.3346/jkms.2018.33.e213

    Article  PubMed  PubMed Central  Google Scholar 

  25. Caporali R, Zavaglia D (2019) Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 37:485–495

    PubMed  Google Scholar 

  26. Harnett J, Gerber R, Gruben D et al (2016) Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in Ra patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm 22:1457–1471. https://doi.org/10.18553/jmcp.2016.22.12.1457

    Article  PubMed  Google Scholar 

  27. Mori S, Yoshitama T, Ueki Y (2018) Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naïve and experienced patients. Intern Med 57:663–670. https://doi.org/10.2169/internalmedicine.9341-17

    Article  CAS  PubMed  Google Scholar 

  28. Iwamoto N, Tsuji S, Takatani A et al (2017) Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One 12:e0177057. https://doi.org/10.1371/journal.pone.0177057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lee HS, Korman BD, Le JM et al (2009) Genetic risk factors for rheumatoid arthritis differ in Caucasian and Korean populations. Arthritis Rheum 60:364–371. https://doi.org/10.1002/art.24245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kim K, Bang SY, Ikari K et al (2016) Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis. Sci Rep 6:27563. https://doi.org/10.1038/srep27563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yamamoto K, Okada Y, Suzuki A, Kochi Y (2015) Genetics of rheumatoid arthritis in Asia - present and future. Nat Rev Rheumatol 11:375–379

    Article  CAS  PubMed  Google Scholar 

  32. Danila MI, Reynolds RJ, Tiwari HK, Bridges SL (2013) Editorial: ethnic-specific genetic analyses in rheumatoid arthritis: incremental gains but valuable contributions to the big picture. Arthritis Rheum 65:3014–3016

    Article  PubMed  PubMed Central  Google Scholar 

  33. Griffiths B, Situnayake RD, Clark B et al (2000) Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study. Rheumatology 39:857–864. https://doi.org/10.1093/rheumatology/39.8.857

    Article  CAS  PubMed  Google Scholar 

  34. Reed GW, Gerber RASY (2017) TNFI and tofacitinib monotherapy and comparative effectiveness in clinical practice: results from Corrona registry. Ann Rheum Dis 76:60

    Google Scholar 

  35. Li ZG, Liu Y, Xu HJ et al (2018) Efficacy and safety of tofacitinib in Chinese patients with rheumatoid arthritis. Chin Med J 131:2683–2692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Strand V, Kremer JM, Gruben D et al (2017) Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res 69:592–598. https://doi.org/10.1002/acr.23004

    Article  CAS  Google Scholar 

  37. Finckh A, Tellenbach C, Herzog L et al (2020) Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 6:e001174. https://doi.org/10.1136/rmdopen-2020-001174

    Article  PubMed  PubMed Central  Google Scholar 

  38. Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A et al (2018) Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia 56:203–211. https://doi.org/10.5114/reum.2018.77971

    Article  PubMed  PubMed Central  Google Scholar 

  39. Taylor PC (2019) Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/key225

    Article  PubMed  PubMed Central  Google Scholar 

  40. Machado MAdÁ, de Moura CS, Guerra SF et al (2018) Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther 20:60. https://doi.org/10.1186/s13075-018-1539-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Orbai AM, Bingham CO (2015) Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep 17:28

    Article  PubMed  Google Scholar 

  42. Hendrikx J, De Jonge MJ, Fransen J et al (2016) Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis. RMD Open 2:e000202

    Article  PubMed  PubMed Central  Google Scholar 

  43. Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108–1123. https://doi.org/10.1002/art.41752

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

None declared.

Funding

None declared.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial Geriatrics Institute, 106 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China

    Yunzhen Shi, Yuesheng Xie, Guangfeng Zhang & Yuan Feng

Authors
  1. Yunzhen Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuesheng Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guangfeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yunzhen Shi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of Guangdong General Hospital [No. GDREC2020256H].

Consent to participate

Because of the retrospective nature of the study, the requirement of informed consent was waived.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shi, Y., Xie, Y., Zhang, G. et al. Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China. Intern Emerg Med 17, 703–714 (2022). https://doi.org/10.1007/s11739-021-02852-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-021-02852-3

Keywords

Search

Navigation